Efficacy and safety of Chlorpromazine in the treatment of COVID-19 patients

INTERVENTION: Intervention 1: Intervention group: Patients with covid 19 infection will receive standard treatment of Atazanavir/Ritonavirdrug 300/100 mg (Razavi Pharmaceutical Institute) once daily in addition to chlorpromazine 25 mg (Tehran Shimi Company) three times a day. Maximum time of intervention will be 14 days. Intervention 2: Control group: Patients with covid 19 infection will receive standard treatment of Atazanavir/Ritonavirdrug 300/100 mg (Razavi Pharmaceutical Institute) once daily in addition to Placebo three times a day. Maximum time of intervention will be 14 days. CONDITION: COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Patients level of Spo2. Timepoint: daily. Method of measurement: puls oximetr. SECONDARY OUTCOME: Days stayed in the hospital. Timepoint: At the end of the study. Method of measurement: Documentation of the hospital stay according to patients chart. Days stayed in the Intensive Care Unit. Timepoint: During the study. Method of measurement: Documenting the days stayed in the Intensive Care Unit. Mortality rate. Timepoint: At the end of the study. Method of measurement: Follow up of patients and documentation of the mortality. Need to ICU admission. Timepoint: During the study. Method of measurement: Follow up of patient and documentation of the ICU admission. INCLUSION CRITERIA: all admitted patients with covid ‐19 infection based on clinical findings ,PCR or lung CT abnormality consistent with covid‐19 spo2 bellow 93 mmHg age above 18 years old